Showing 1 - 20 results of 31 for search '"ИММУНОГИСТОХИМИЧЕСКИЙ МЕТОД"', query time: 0.87s Refine Results
  1. 1
  2. 2
    Academic Journal

    Source: Gastroenterologìa, Vol 53, Iss 2, Pp 128-131 (2019)
    GASTROENTEROLOGY; Том 53, № 2 (2019); 128-131
    Гастроэнтерология-Gastroenterologìa; Том 53, № 2 (2019); 128-131
    Гастроентерологія-Gastroenterologìa; Том 53, № 2 (2019); 128-131

    File Description: application/pdf

  3. 3
  4. 4
    Academic Journal

    File Description: application/pdf

    Relation: Гринь В. Г. Імуногістохімічний аналіз пейєрових бляшок тонкої кишки білих щурів у нормі / В. Г. Гринь // Вісник проблем біології і медицини. – 2020. – Вип. 1 (155). – С. 292–296.; https://repository.pdmu.edu.ua/handle/123456789/12304

  5. 5
    Academic Journal

    Source: Malignant tumours; Том 9, № 4 (2019); 25-31 ; Злокачественные опухоли; Том 9, № 4 (2019); 25-31 ; 2587-6813 ; 2224-5057

    File Description: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/697/478; Rangachari D, Costa DB. From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. J Clin Oncol. 2019 Jun 2: JCO1901207. doi:10.1200/JCO/19.01207. [Epub ahead of print].; Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 Jun 2: JCO1900934. doi:10.1200/JCO.19.00934. [Epub ahead of print].; Mok TSK, Wu YL, Kudaba I, Kowalski DM, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, openlabel, controlled, phase 3 trial. Lancet. 2019 May 4;393 (10183):1819 – 1830.; U. S. Food & Drug Administration. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. https://www.fda.gov/drugs/fda-approves-pembrolizumab-combinationchemotherapy-first-line-treatment-metastatic-squamous-nsclc Accessed August 12, 2019.; Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017 Nov;22 (11):1392 – 1399.; Laktionov K. K., Sarantseva K. A., Breder V. V., Okruzhnova M. A., Peregudova M. V. Immunotherapy for non-small cell lung cancer treatment. Malignant tumours. 2016; (3):17 – 24. (In Russ.).; NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 5.2019. https://www.nccn.org/professionals /physician_gls /PDF /nscl.pdf; Rittmeyer A, Barlesi F, Waterkamp D, Park K, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389 (10066):255 – 265.; Kazandjian D, Suzman DL, Blumenthal G, Mushti S, et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist. 2016 May;21 (5):634 – 42.; Antonia SJ, Villegas A, Daniel D, Vicente D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377 (20):1919 – 1929.; Imyanitov EN, Demidova IA, Gordiev MG, Filipenko ML, et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Mol Diagn Ther. 2016 Aug;20 (4):401 – 6.; Zavalishina L, Tsimafeyeu I, Povilaitite P, Raskin G, et al. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer. Virchows Arch. 2018 Dec;473 (6):719 – 724.; Isobe K, Kakimoto A, Mikami T, Kaburaki K, et al. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncol Rep. 2018 Jul;40 (1):331 – 338.; Tsao MS, Kerr KM, Kockx M, Beasley MB, et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018 Sep;13 (9):1302 – 1311.; Ratcliffe MJ, Sharpe A, Midha A, Barker C, et al. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Jul 15;23 (14):3585 – 3591.; Hendry S, Byrne DJ, Wright GM, Young RJ, et al. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. J Thorac Oncol. 2018 Mar;13 (3):367 – 376.; Rimm DL, Han G, Taube JM, Yi ES et al. A prospective, multiinstitutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol. 2017;3:1051 – 1058.; Tsimafeyeu I, Imyanitov E, Zavalishina L, et al. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. Sci Rep. 2020;10 (1):3928. Published 2020 Mar 3. doi:10.1038/s41; https://www.malignanttumors.org/jour/article/view/697

  6. 6
  7. 7
  8. 8
  9. 9
    Academic Journal

    Source: Journal Infectology; Том 6, № 1 (2014); 41-46 ; Журнал инфектологии; Том 6, № 1 (2014); 41-46 ; 2072-6732 ; 10.22625/2072-6732-2014-6-1

    File Description: application/pdf

    Relation: https://journal.niidi.ru/jofin/article/view/219/212; Kulchavenya EV. Some aspects of Urogenital Tuberculosis. Int. J. Nephrol. Urol. 2010; 2(2):351-60.; Nersesyan AA, еt al. Problemy tuberkuleza. 2005; 8: 32-5.; Nersesyan AA, Zyuzya YuR, Merkuryeva YaA. Tuberkulez i bolezni legkikh. 2010; 7: 58-62.; Fligel DM, Zyuzya YuR, Alvares Figeroa MV, et al. Meditsinskiy vestnik Bashkortostana. 2010; 3: 91-2.; Kulchavenya YeV, Kholtobin DP, Brizhatyuk YeV. Byulleten sibirskoy meditsiny. 2011; 2: 83-7.; Bogin YuB, et al. Diagnostika nefrotuberkuleza v sovremennykh usloviyakh [Diagnosis of nephrotuberculosis in modern conditions] In: Vnelegochnyy tuberkulez – aktualnaya problema zdravookhraneniya [Extrapulmonary tuberculosis – current health problem]. Proceedings of Russian scientific and practical conference. St.Petersburg (Russia); 1997. р 29. Russian.; Shapapiro AL, Viter VI. Urologiya i nefrologiya. 1989; 1: 12-5.; Hemal AK, at al. Polymerase chain reaction in clinically suspected genitourinary tuberculosis: comparison with intravenous urography, bladder biopsy, and urine acid fast bacilli culture. Urology. 2000; 56(4):570-4.; Kulchavenya YeV, Brizhatyuk YeV. Urologiya. 2006; 3: 61-6.; Benchekroun A, at al. Urogenital tuberculosis. 80 . Ann Urol (Paris). 1998; 32(2): 89-94.; Ulrichs T, at al. Modified immunohistological staining allows detection of Zeil-Neelsen – negative Mycobacterium tuberculosis organisms and their precise ocalization in human tissue. J. Pathol. 2005; 205: 633-640.; Salomao R, at al. TLR signaling pathway in patients with sepsis. Shock. 2008; 30(1): 73-7.; Nasu, K. Pattern Recognition via the Toll-Like Receptor System in the Human Female Genital Tract / K. Nasu, H. Narahara // Human Immunology. - 2005; 66(5): 469-82.; Brightbill HD, at al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors .Science. 1999; 285(5438):732-6.; Means TK, Wang S, Lien E, et al. Human Toll-like receptors mediate cellular activation by Mycobacterium tuberculosis . J. Immunol. 1999; 163: 3920-7.; BhattK, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J. Clin. Immunol. 2007; 27: 347–362.; Teixeira-Coelho M , at al. TLR2 deficiency by compromising p19 (IL-23) expression limits Th 17 cell responses to Mycobacterium tuberculosis. Int Immunol. 2011; 23: 89–96.; Fenhalls G, at al. Associations between Toll-like receptors and interleukin-4 in the lungs of patients with tuberculosis. Am. J. Respir. Cell Mol. Biol. 2003; 29: 28-38.; Yunkerov VI, Grigoryev SG. Mathematical and statistical analysis of medical research data. Lectures for graduate students and adjuncts. St.Petersburg (Russia): VMA; с2005. 266 р. Russian.; https://journal.niidi.ru/jofin/article/view/219

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
    Academic Journal

    File Description: application/pdf

    Relation: Ніколенко Д. Є. Імуногістохімічні особливості неінвазивної солідної форми внутрішньопротокового раку молочної залози / Д. Є. Ніколенко // Актуальні проблеми сучасної медицини: Вісник української медичної стоматологічної академії. – 2010. – Вип. 4, т. 10. – С. 112–114.; https://repository.pdmu.edu.ua/handle/123456789/7984

  18. 18
  19. 19
  20. 20